Autologous Mesenchymal Stem Cell Therapy (Tisch Multiple Sclerosis Research Center Of New York)

N/A

Report date: 2025/03/13 20:00:06

Base Information

Drug NameAutologous Mesenchymal Stem Cell Therapy (Tisch Multiple Sclerosis Research Center Of New York)

Drug Alias NameAutologous Mesenchymal Stem Cell-derived Neural ProgenitorsAutologous MSC-NP

ClassificationCell and gene therapy > Cell therapy > Somatic cell > Neural progenitor cell therapyCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Cell therapy > Source of cells > Mesenchymal Stem Cell-Derived +[4]

Mechanisms of ActionStem cell replacements

TargetsNot applicable

Therapy Area/IndicationsMultiple Sclerosis

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesTisch Multiple Sclerosis Research Center Of New York

China Registration ClassN/A

Develop Information

Active CompaniesTisch Multiple Sclerosis Research Center Of New York

Inactive CompaniesN/A

Active IndicationsMultiple Sclerosis

Inactive IndicationsN/A

Other Information

ATC CodeN/A